Brown Advisory Inc. Sells 2,105 Shares of Eli Lilly and Company (NYSE:LLY)

Brown Advisory Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,856 shares of the company's stock after selling 2,105 shares during the quarter. Brown Advisory Inc.'s holdings in Eli Lilly and Company were worth $82,493,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. CWA Asset Management Group LLC grew its stake in Eli Lilly and Company by 11.9% in the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after acquiring an additional 724 shares during the period. Knightsbridge Asset Management LLC increased its position in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the last quarter. Centerpoint Advisory Group bought a new stake in Eli Lilly and Company during the fourth quarter worth $514,000. Kentucky Trust Co bought a new position in Eli Lilly and Company during the fourth quarter worth about $834,000. Finally, CSM Advisors LLC increased its holdings in shares of Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after acquiring an additional 245 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Finally, HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,002.80.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $45.20 during trading on Tuesday, hitting $776.26. The stock had a trading volume of 5,961,205 shares, compared to its average volume of 3,485,577. The stock's 50 day moving average is $820.91 and its two-hundred day moving average is $814.03. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market cap of $735.69 billion, a price-to-earnings ratio of 66.29, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 EPS. The firm's revenue was up 45.2% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.